% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Akbaba:166614,
author = {S. Akbaba$^*$ and A. Rühle$^*$ and S. Rothhaar and C.
Zamboglou$^*$ and E. Gkika$^*$ and R. Foerster and L.
Oebel$^*$ and T. Klodt$^*$ and H. Schmidberger$^*$ and A.-L.
Grosu$^*$ and J. Debus and T. Bostel$^*$ and N. H.
Nicolay$^*$},
title = {{T}reatment outcomes of elderly salivary gland cancer
patients undergoing radiotherapy - results from a large
multicenter analysis.},
journal = {Radiotherapy and oncology},
volume = {156},
issn = {0167-8140},
address = {Amsterdam [u.a.]},
publisher = {Elsevier Science},
reportid = {DKFZ-2020-03050},
pages = {266-274},
year = {2021},
note = {Volume 156, March 2021, Pages 266-274 / #LA:E055#},
abstract = {To evaluate oncological outcomes and treatment-related
toxicities of elderly salivary gland cancer patients
undergoing (chemo)radiotherapy.Local/locoregional control
(LRC), progression-free survival (PFS) and overall survival
(OS) of elderly patients ≥65 years with primary salivary
gland cancers undergoing (chemo)radiotherapy between 2005
and 2020 at three tertiary cancer centers were calculated.
The impact of clinicopathological and treatment parameters
on outcomes were analyzed, and acute and chronic toxicities
were quantified.288 elderly salivary gland cancer patients
were included in this multicenter analysis, and their median
LRC, PFS and OS amounted to 113, 39 and 75 months,
respectively. Age, performance status, comorbidities,
definitive vs. adjuvant (chemo)radiotherapy as well as
locally/locoregionally advanced cancers and distant
metastases correlated with reduced outcomes in elderly
salivary gland patients. Patients receiving dose-escalated
radiotherapy (total doses >70 GyEQD2) with carbon ion boost
radiation resulted in improved LRC, but no improvements in
PFS or OS. Concomitant chemoradiotherapy did not improve
treatment outcomes in elderly salivary gland carcinoma
patients. Radiotherapy of elderly salivary gland cancer
patients resulted in moderate higher-grade toxicities
despite dose escalation with 70 $(24.3\%)$ and 48 patients
$(16.7\%)$ experiencing acute and chronic grade 3
toxicities, respectively. No grade 4/5 toxicities were
observed in this patient cohort.Data from the largest
multicenter analysis of elderly salivary gland cancer
patients undergoing (chemo)radiotherapy demonstrate
favorable LRC and tolerable toxicity rates. Decision-making
for these vulnerable patients should be based on patient
performance rather than chronological patient age.},
keywords = {Chemotherapy (Other) / Elderly patients (Other) / Geriatric
patients (Other) / Head-and-neck cancer (Other) /
Radiotherapy (Other) / Salivary gland cancer (Other)},
cin = {FM01 / FR01 / HD01 / E050 / E055},
ddc = {610},
cid = {I:(DE-He78)FM01-20160331 / I:(DE-He78)FR01-20160331 /
I:(DE-He78)HD01-20160331 / I:(DE-He78)E050-20160331 /
I:(DE-He78)E055-20160331},
pnm = {315 - Bildgebung und Radioonkologie (POF4-315)},
pid = {G:(DE-HGF)POF4-315},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:33359662},
doi = {10.1016/j.radonc.2020.12.024},
url = {https://inrepo02.dkfz.de/record/166614},
}